The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Omics-Based Clinical Trials Market Progress Between 2026 And 2030?
The omics-based clinical trials market has shown robust expansion in recent years. Its valuation is expected to increase from $31.71 billion in 2025 to $34.49 billion in 2026, marking a compound annual growth rate (CAGR) of 8.8%. The growth observed historically can be attributed to several factors, including the rising complexity of clinical trial designs, the expansion of genomic and proteomic research, an escalating demand for personalized therapies, the enhancement of clinical research infrastructure, and increased collaborations between pharmaceutical companies and academic institutions.
The omics-based clinical trials market is anticipated to experience robust expansion over the coming years. This market is projected to reach a size of $47.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. The momentum behind this growth during the forecast period stems from the increasing integration of precision medicine techniques, a rise in investments directed at data-centric clinical trials, the broader deployment of AI for patient recruitment, the increasing regulatory endorsement of omics-based endpoints, and a heightened demand for streamlined trial outcomes. Significant trends expected during this period encompass the growing adoption of biomarker-driven trial structures, an increased application of multi-omics in patient stratification, the expanding integration of real-world evidence analytics, a proliferation of precision oncology clinical trials, and a strengthened emphasis on data-focused trial optimization.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp
What Key Factors Are Shaping The Omics-Based Clinical Trials Market Landscape?
The rising demand for personalized medicine is projected to fuel the expansion of the omics-based clinical trials market in the foreseeable future. Personalized medicine is defined as a medical approach that customizes disease prevention, diagnosis, and treatment to the unique characteristics of each patient. The need for personalized medicine is escalating due to advancements in genomic technologies, which facilitate faster and more cost-effective analysis of individual genetic profiles to guide specific treatments. Omics-based clinical trials support personalized medicine by enabling the identification of individual genetic, proteomic, and metabolic profiles, thereby allowing for more targeted and effective treatment strategies tailored to each patient. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022, with the 2023 approvals also encompassing seven oncology therapies and three treatments targeting various other conditions. Thus, the increasing demand for personalized medicine is driving the growth of the omics-based clinical trials market.
How Is The Omics-Based Clinical Trials Market Segmented Across Different Segment Categories?
The omics-based clinical trials market covered in this report is segmented –
1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories
Subsegments:
1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping
3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis
4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling
What Market Trends Are Affecting The Omics-Based Clinical Trials Market?
Leading companies active in the omics-based clinical trials market are prioritizing inventive solutions, like HiFi sequencing technology, to boost the accuracy, speed, and depth of multi-omics data analysis, consequently improving trial outcomes and personalized treatment strategies. HiFi sequencing is characterized as a next-generation sequencing (NGS) technology that yields long, highly precise reads via circular consensus sequencing (CCS), enabling comprehensive and exact analysis of genomes, transcriptomes, and epigenomes. For example, in October 2024, Pacific Biosciences of California Inc., a US-based biotechnology company, in collaboration with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, launched a cutting-edge laboratory to accelerate genomics innovation in Singapore utilizing advanced long-read sequencing technology. This facility allows researchers to conduct sophisticated genomic studies with greater accuracy and pace. It supports a wide array of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. The lab additionally promotes collaboration among global scientists and local institutions, aiming to expedite discoveries in personalized medicine, rare disease diagnostics, and precision oncology. Moreover, it offers training programs and shared access to high-throughput sequencing infrastructure, thereby fostering capacity-building and innovation across the Asia-Pacific region.
Which Organizations Play A Role In The Omics-Based Clinical Trials Market Landscape?
Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.
Get The Full Omics-Based Clinical Trials Market Report:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report
Where Is The Omics-Based Clinical Trials Market Primarily Concentrated By Region?
North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Omics-Based Clinical Trials Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report
Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2026, By The Business Research Company
Medical And Diagnostic Laboratory Services Market Report 2026
Medical And Diagnostic Laboratory Services Market Report
Lab Supplies Market Report
https://www.thebusinessresearchcompany.com/report/lab-supplies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model